探戈治疗

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $27 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 评级变动
  Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $68
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66
  \u5e02\u573a\u8d44\u8baf · 2026/6/10
• 评级变动
  A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $42
  \u5e02\u573a\u8d44\u8baf · 2026/6/9
• Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)
  TipRanks · 2026/8/12
• Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Mizuho Securities Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• 评级变动
  H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/5/22
• 评级变动
  A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $27 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• 评级变动
  Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/7/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。